tiprankstipranks
Charles River Laboratories Intl (CRL)
NYSE:CRL
Want to see CRL full AI Analyst Report?

Charles River Labs (CRL) Price & Analysis

591 Followers

CRL Stock Chart & Stats

$226.58
-$2.71(-1.18%)
At close: 4:00 PM EDT
$226.58
-$2.71(-1.18%)

Bulls Say, Bears Say

Bulls Say
Cash GenerationConsistent positive operating and free cash flow provide durable financial flexibility despite reported earnings weakness. Strong cash conversion supports debt service, targeted share repurchases and funding of strategic investments or acquisitions without immediate reliance on external capital markets.
Diversified Outsourced ServicesA broad fee-for-service model across research models, discovery/safety and manufacturing creates multi-year, repeatable revenue streams tied to R&D pipelines. Regulatory barriers, specialized infrastructure and long project engagements enhance customer stickiness and defendable market position over the medium term.
Cost-Savings & Margin Recovery PlanMeaningful, multi-year cost reduction targets and targeted margin expansion are structural levers that can sustainably improve operating profitability. Cumulative savings of this scale can offset secular revenue softness, boost free cash flow, and fund reinvestment or deleveraging over the next several quarters.
Bears Say
Revenue & Profitability DeteriorationA pronounced TTM revenue decline and swing to losses indicate structural demand or portfolio shifts that materially impair earnings power. Sustained top-line weakness reduces leverage benefits of fixed-cost recovery, pressures returns on capital, and raises execution risk for margin-restoration plans.
Elevated LeverageMaterial leverage limits flexibility to invest, pursue bolt-on M&A or weather prolonged demand softness. With profitability under pressure, higher leverage raises refinancing and interest-rate sensitivity, constrains capital allocation choices, and can amplify downside if cash generation weakens.
Segment Operational PressuresCore segments face persistent, structural headwinds: higher NHP sourcing costs, study-start timing and lower small-model volumes depress margins. These operational challenges are tied to supply dynamics and study cadence, which can take multiple quarters to normalize and limit near-term margin resilience.

Charles River Labs News

CRL FAQ

What was Charles River Laboratories Intl’s price range in the past 12 months?
Charles River Laboratories Intl lowest stock price was $144.26 and its highest was $267.99 in the past 12 months.
    What is Charles River Laboratories Intl’s market cap?
    Charles River Laboratories Intl’s market cap is $11.20B.
      When is Charles River Laboratories Intl’s upcoming earnings report date?
      Charles River Laboratories Intl’s upcoming earnings report date is Nov 11, 2026 which is in 97 days.
        How were Charles River Laboratories Intl’s earnings last quarter?
        Charles River Laboratories Intl released its earnings results on Aug 05, 2026. The company reported $3.02 earnings per share for the quarter, beating the consensus estimate of $2.767 by $0.253.
          Is Charles River Laboratories Intl overvalued?
          According to Wall Street analysts Charles River Laboratories Intl’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does Charles River Laboratories Intl pay dividends?
            Charles River Laboratories Intl does not currently pay dividends.
            What is Charles River Laboratories Intl’s EPS estimate?
            Charles River Laboratories Intl’s EPS estimate is 3.
              How many shares outstanding does Charles River Laboratories Intl have?
              Charles River Laboratories Intl has 48,167,730 shares outstanding.
                What happened to Charles River Laboratories Intl’s price movement after its last earnings report?
                Charles River Laboratories Intl reported an EPS of $3.02 in its last earnings report, beating expectations of $2.767. Following the earnings report the stock price went up 11.362%.
                  Which hedge fund is a major shareholder of Charles River Laboratories Intl?
                  Currently, no hedge funds are holding shares in CRL
                  What is the TipRanks Smart Score and how is it calculated?
                  Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                    Company Description

                    Charles River Laboratories Intl

                    Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

                    Charles River Labs (CRL) Earnings & Revenues

                    CRL Company Deck

                    CRL Earnings Call

                    Q2 2026
                    0:00 / 0:00
                    Earnings Call Sentiment|Positive
                    The call highlighted clear operational progress: better-than-expected Q2 results, sequential margin improvement (420 bps), stronger DSA demand signals with bookings/backlog gains and raised full-year guidance (organic revenue guidance improved by ~150 bps and EPS guidance raised). Strategic actions (divestitures, NHP supply integration, partnerships, AI/digital investments and lab expansions) are positioned to drive further margin and growth upside. However, notable near-term challenges remain: RMS softness driven by North American academic/government funding constraints, Q2 free cash flow decline, higher corporate costs and an elevated tax rate headwind, plus timing risk with material NHP sourcing benefits largely back-loaded into Q4 and pricing improvements not yet realized. On balance, positives (outperformance, raised guidance, bookings/backlog strength, margin momentum and strategic partnerships) outweigh the lowlights, though some operational and timing risks persist.View all CRL earnings summaries

                    CRL Revenue Breakdown

                    21.07%21.07%59.84%19.09%
                    21.07% RMS
                    59.84% DSA
                    19.09% Manufacturing
                    tipranks

                    CRL Stock 12 Month Forecast

                    Average Price Target

                    $258.09
                    ▲(13.91% Upside)
                    {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"160":"$160","311":"$311","197.75":"$197.8","235.5":"$235.5","273.25":"$273.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":310,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$310.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":258.09090909090907,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$258.09</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":213,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$213.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[160,197.75,235.5,273.25,311],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,232.51,238.47076923076924,244.43153846153845,250.3923076923077,256.3530769230769,262.31384615384616,268.2746153846154,274.2353846153846,280.19615384615383,286.1569230769231,292.1176923076923,298.0784615384615,304.03923076923076,{"y":310,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,232.51,234.47776223776222,236.44552447552445,238.4132867132867,240.38104895104894,242.34881118881117,244.3165734265734,246.28433566433566,248.2520979020979,250.21986013986012,252.18762237762235,254.1553846153846,256.1231468531468,{"y":258.09090909090907,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,232.51,231.00923076923075,229.50846153846152,228.0076923076923,226.50692307692307,225.00615384615384,223.5053846153846,222.0046153846154,220.50384615384615,219.00307692307692,217.50230769230768,216.00153846153847,214.50076923076924,{"y":213,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":166.91,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":161.25,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":170.48,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":180.07,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":176.09,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":199.48,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":213.22,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":178.61,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":174.9,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":165.78,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":182.07,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":229.09,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":232.51,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    Idexx Laboratories
                    Neogen
                    Revvity
                    Qiagen
                    Medpace Holdings

                    Ownership Overview

                    1.10%44.43%4.55%18.58%
                    4.55% Other Institutional Investors
                    18.58% Public Companies and
                    Individual Investors
                    Popular Stocks